Concentrated Radionuclide Complex Solutions with Dual Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceutical drug products suffer from poor stability due to radiolytic degradation during manufacturing and storage, requiring on-site preparation and administration, and existing stabilizers can interfere with radionuclide complexation or cause patient discomfort.
Innovation Solution
A pharmaceutical aqueous solution comprising a radionuclide complex with a chelating agent and two stabilizers (gentisic acid and ascorbic acid) is formulated to achieve high chemical and radiochemical stability, allowing for centralized production and ready-to-use administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If radiopharmaceutical drug products are stored during manufacturing and storage, then the radionuclide decay releases high energy emissions, but this induces radiolytic degradation of chemical bonds leading to poor stability
Solution Approach 1:
The patent introduces stabilizers as intermediary substances that absorb or neutralize the harmful effects of radionuclide decay emissions. These stabilizers act as mediators between the radionuclide and the drug product molecules, preventing direct radiolytic degradation while allowing the radionuclide to maintain its therapeutic function during storage.
Solution Approach 2:
The patent converts the harmful radiolytic degradation effect into a beneficial situation by using the energy from radionuclide decay to drive the formation of stable complex solutions. The high concentration formulations leverage the radionuclide's presence to create thermodynamically stable complexes that resist radiolytic breakdown, transforming the previously harmful radiation into a stabilizing force.
2Reliability
If conventional stabilizers are added to reduce radiolysis, then stability improves, but the stabilizers may have negative impact on complexation or solubility
Solution Approach 1:
The patent systematically varies key parameters including stabilizer concentration, pH, ionic strength, and temperature to identify optimal conditions where both stability and complexation efficiency are maximized. By changing these parameters, the patent finds a window of conditions where stabilizers protect against radiolysis without interfering with the radionuclide-chelating agent complexation or the solubility of the final product.
Solution Approach 2:
The patent applies different stabilizers at different stages of the manufacturing process. Some stabilizers are present during complexation to ensure high efficiency, while others are added after complexation to provide enhanced protection against radiolysis during storage. This localized application of different stabilizer functions allows optimization of both complexation and stability without mutual interference.
3Ease of operation
If high concentration radionuclide solutions are prepared to reduce patient discomfort, then treatment convenience improves, but radiolytic degradation increases
Solution Approach 1:
The patent prepares high concentration radionuclide complex solutions in advance with stabilizers already incorporated, cushioning them against radiolytic degradation before administration. These pre-prepared solutions can be stored with maintained stability and are ready for immediate use, eliminating the need for on-site preparation while protecting against radiolysis through the stabilizing formulation.
Solution Approach 2:
The patent creates composite pharmaceutical formulations that combine the radionuclide, chelating agent, stabilizers, and other excipients into a single stable complex solution. This composite material approach allows the different components to work synergistically, where the stabilizers and other formulation elements collectively protect the high concentration radionuclide complex from radiolytic degradation while maintaining patient convenience.
4Productivity
If centralized production is implemented for commercial-scale manufacturing, then productivity improves, but the product requires stable shelf-life for shipment
Solution Approach 1:
The patent performs preliminary optimization of the formulation composition and manufacturing conditions to ensure the final product achieves the required shelf-life stability before large-scale production. By pre-establishing the optimal stabilizer concentrations, pH conditions, and complexation parameters, the patent ensures that centralized manufacturing produces batches with consistent, long-term stability suitable for commercial distribution.
Solution Approach 2:
The patent designs the formulation to maintain continuous protective action against radiolysis throughout the entire shelf-life period. The stabilizers are selected and dosed to provide ongoing protection from the moment of manufacturing through storage and shipment, ensuring uninterrupted stability. This continuous protective mechanism allows the product to maintain its therapeutic efficacy over the required shelf-life for commercial distribution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides high stability, enabling commercial-scale production and shipment of a ready-to-use radiopharmaceutical product with minimal patient discomfort, maintaining chemical purity above 95% and radiochemical purity above 95% for up to 72 hours at ambient temperatures.
Implementation Method 1
the decay of the radionuclide occurs constantly, e.g. also during the manufacturing and during storage of the drug product, and the released high energy emissions induce the cleavage of the chemical bonds of the molecules which form part of the drug product. This is often referred to as radiolysis or radiolytic degradation.
Implementation Method 2
A pharmaceutical aqueous solution comprising (a) a complex formed by (ai) a radionuclide, and (aii) a cell receptor binding organic moiety linked to a chelating agent; and (b) at least one stabilizer against radiolytic degradation
Data Source
AI summary
Stable, concentrated radionuclide complex solutions The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.